Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.49M | 6.32M | 6.65M | 7.14M | 8.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.49M | 6.32M | 6.65M | 7.14M | 8.47M |
| Cost of Revenue | 84.42M | 87.47M | 91.90M | 99.54M | 108.36M |
| Gross Profit | -77.93M | -81.15M | -85.25M | -92.41M | -99.89M |
| SG&A Expenses | 54.56M | 57.17M | 61.35M | 67.59M | 77.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 138.98M | 144.64M | 153.25M | 167.13M | 186.11M |
| Operating Income | -132.49M | -138.32M | -146.60M | -159.99M | -177.64M |
| Income Before Tax | -126.00M | -129.91M | -136.32M | -156.09M | -171.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -126.00 | -129.91 | -136.32 | -156.09 | -171.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.00M | -129.91M | -136.32M | -156.09M | -171.52M |
| EBIT | -132.49M | -138.32M | -146.60M | -159.99M | -177.64M |
| EBITDA | -120.50M | -125.84M | -133.70M | -145.34M | -161.61M |
| EPS Basic | -1.05 | -1.09 | -1.15 | -1.32 | -1.45 |
| Normalized Basic EPS | -0.65 | -0.68 | -0.71 | -0.75 | -0.83 |
| EPS Diluted | -1.05 | -1.09 | -1.15 | -1.32 | -1.45 |
| Normalized Diluted EPS | -0.65 | -0.68 | -0.71 | -0.75 | -0.83 |
| Average Basic Shares Outstanding | 478.67M | 476.80M | 475.15M | 473.70M | 472.47M |
| Average Diluted Shares Outstanding | 478.67M | 476.80M | 475.15M | 473.70M | 472.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |